<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690947</url>
  </required_header>
  <id_info>
    <org_study_id>Z181100001718079</org_study_id>
    <nct_id>NCT03690947</nct_id>
  </id_info>
  <brief_title>Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME</brief_title>
  <official_title>Randomized, Double-blinded, Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate if combination of intravitreal ranibizumab with
      micropulse laser shows non inferiority compared to intravitreal ranibizumab only in diabetic
      macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the efficacy of intravitreal ranibizumab injections compared to combination
      with Micropulse Laser in Chinese patients with visual impairment in DME.

      The result of the study will be used to support new therapy in DME patients in China.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity changes</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the changes of BCVA between two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Macular Thickness changes</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the changes of CMT between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Combination Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal Ranibizumab Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ranibizumab</intervention_name>
    <description>All subjections received 3 initial Ranibizumab injections</description>
    <arm_group_label>Combination Therapy Group</arm_group_label>
    <arm_group_label>Intravitreal Ranibizumab Group</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Micropulse Laser</intervention_name>
    <description>After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists</description>
    <arm_group_label>Combination Therapy Group</arm_group_label>
    <other_name>Macular Laser Photocoagulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ranibizumab as needed</intervention_name>
    <description>After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization</description>
    <arm_group_label>Intravitreal Ranibizumab Group</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form must be signed before any tests or procedures are done

          -  Male or female of 30 to 80 years of age (inclusive) at the first screening visit

          -  Diagnosis of type 2 diabetes, with fasting blood glucose≤10mmol/L, HbA1C≤10.0%

          -  Diabetic medication must be stable for at least 3 months before first screening visit
             and remain stable during study

          -  Diagnosis of non-proliferative diabetic retinopathy with diabetic macular edema
             resulting in visual acuity reduction

          -  Study eye's BCVA between 24 to 78 ETDRS letters at screening and baseline of the study

          -  Macular edema of the study eye and central retinal thickness ≥300 µm determined by
             SD-OCT

          -  Study eye had not had grid pattern photocoagulation, intraocular surgery, intravitreal
             corticosteroid injections and intravitreal anti-VEGF injections for at least 3 months
             before baseline

          -  Non-study eye's BCVA ≥ 24 ETDRS letters at screening and baseline of the study

          -  Non-study eye had not had intravitreal anti-VEGF injections for at least 3 months
             before baseline

          -  If both eyes qualify, then investigators will choose an eye with worse BCVA as study
             eye. Only study eye will receive intravitreal ranibizumab and/or Micropulse Laser
             treatment

        Exclusion Criteria:

          -  Failure to follow study or follow-up procedures

          -  Pregnant or breast-feeding woman and woman without adequate method of contraception

          -  History of stroke or myocardial infarction within 3 months before screening

          -  Renal failure or creatinine &gt; 2.0 mg/dl

          -  Uncontrolled systemic diseases or systemic treatment that may affect results of the
             study

          -  Active ocular or intraocular infections of either eye

          -  Neovascularization of the iris or neovascular glaucoma of either eye

          -  A history of uveitis or vitreous macular traction in study eye

          -  Glaucoma or IOP≥24 mmHg of study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaobing Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaobing Yu, M.D.</last_name>
    <phone>+86-010-85132171</phone>
    <email>yuxiaobing@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang</last_name>
      <phone>+8613661174001</phone>
      <email>wangxinannie@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>May 4, 2019</last_update_submitted>
  <last_update_submitted_qc>May 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Hospital</investigator_affiliation>
    <investigator_full_name>Yu Xiaobing</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Email yuxiaobing@sina.com for individual participant data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

